



EFW

PATENTS

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
**MULLIS** )  
) Art Unit: 1644  
Serial No. 10/754,456 )  
) Examiner: Not yet assigned  
Filed: January 9, 2004 )  
)  
For: **CHEMICALLY PROGRAMMABLE** )  
**IMMUNITY** )

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Shirley E. Brosmore  
Reg. No. 56,167

KILPATRICK STOCKTON LLP  
1100 Peachtree Street  
Suite 2800  
Atlanta, Georgia 30309-4530  
(404) 815-6500  
Our Docket: 13139-0104 (44537-280131A)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on July 25, 2005.

Shirley E. Brosmore - Reg. No. 56,167

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/754,456 January 9, 2004 Mullis 1644  13139-0104 (44537-280131A)
Sheet	1	of	1

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	1	6,248,332 B1		Romet-Lemonne et al.	06/19/2001	

## OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	2	BRUNO, JOHN G. ET AL.; "In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection"; <i>Biosensors &amp; Bioelectronics</i> 14 (1999), pp. 457-464	
	3	AHNERT-HILGER, G. ET AL.; "Monoclonal Antibodies Against Tetanus Toxin and Toxoid"; <i>Med Microbiol Immunol</i> ; (1983) 172:123-135	
	4	FINBERG, ROBERT W. ET AL.; "The Use of Antiidiotypic Antibodies as Vaccines Against Infectious Agents"; <i>CRC Critical Reviews in Immunology</i> ; Vol. 7, Issue 4, (1987); pp. 269-284	
	5	GLENNIE, MARTIN J. ET AL.; "Preparation and Performance of Bispecific (F(ab') <sub>2</sub> ; Antibody Containing Thioether-Linked Fab'γ Fragments"; <i>Journal of Immunology</i> ; Vol. 139, No. 7, October 1, 1987, pp. 2367-237	
	6	JAYASENA, SUMEDHA D.; "Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics"; <i>Clinical Chemistry</i> ; Vol. 45; No. 9; (1999) pp. 1628-1650	
	7	RINGQUIST, STEVEN ET AL.; "Anti- $\alpha$ -Selectin Oligonucleotide Ligands Recognize CD62L-Positive Leukocytes: Binding Affinity and Specificity of Univalent and Bivalent Ligands"; <i>Cytometry</i> ; Vol. 33, 1998; pp. 394-405	
	8	COLAS, PIERRE ET AL.; "Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2"; <i>Nature</i> ; Vol. 380; April 11, 1996; pp. 548-550	
	9	WEINER, GEORGE J. ET AL.; "Bispecific Anti-Idiotypic/Anti-CD3 Antibody Therapy of Murine B Cell Lymphoma"; <i>The Journal of Immunology</i> ; Vol. 147, No. 11, December 1, 1991, pp. 4035-4044	
	10	XU, WEI ET AL.; "Anti-peptide aptamers recognize amino acid sequence and bind a protein epitope"; <i>Proc. Natl. Acad. Sci. USA</i> ; Vol. 93, July 1996, pp. 7475-7480	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.